journal article·2021-01

Paclitaxel‐loaded polypeptide‐polyacrylamide nanomicelles overcome drug‐resistance by enhancing lysosomal membrane permeability and inducing apoptosis

Sahar Abbasi, Gholamhossein Yousefi, Ali‐mohammad Tamaddon, Omidreza Firuzi

Publisher page

Abstract

Abstract The aim of the current project was to investigate the in vitro properties of Paclitaxel (PTX)‐loaded pHPMA5kD‐pHis5kD‐pLeu3kD nanomicelles (NMs) on multidrug resistance cell line. Circular dichroism analysis was done to investigate the effect of pH on the secondary structure of the copolymer. Cytotoxicity assay together with fluorescence imaging and flow cytometry were performed to get an insight about toxicity and cellular uptake mechanism of NMs. Acridine orange assay, rhodamine 123 (Rh123) accumulation assay, and apoptosis analysis were conducted for further investigation. It was found that the secondary structure of the copolymer changed in response to pH, PTX‐loaded NMs had higher cytotoxicity on both drug‐sensitive (MES‐SA and MCF‐7) and multidrug resistant cells (MES‐SA/DX5) compared to free PTX, and interestinly free copolymer inhibited the growth of MES‐SA/DX5 cells while it was nontoxic on drug‐sensitive cells. Moreover, the copolymer was able to induce lysosome membrane permeation and increase Rh123 accumulation inside cells indicating inhibition of the P‐gp efflux pumps. Finally, apoptosis was strongly induced in MES‐SA/DX5 cells upon treatment with PTX‐loaded NMs. It can be concluded that the designed hybrid copolymer is a good candidate for in vivo assay and developing a powerful system against multidrug resistance tumors.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Drug Transport and Resistance Mechanisms · Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmacy Hormozgan University of Medical Sciences Bandar Abbas Iran

Department of Pharmaceutics, School of Pharmacy Shiraz University of Medical Sciences Shiraz Iran

Center for Nanotechnology in Drug Delivery, School of Pharmacy Shiraz University of Medical Sciences Shiraz Iran

Medicinal and Natural Products Chemistry Research Center Shiraz University of Medical Sciences Shiraz Iran

References (54)

Show source-provided references
1. 10.1002/app.4323310.1002/app.43233 ↗
2. 10.1016/j.colsurfa.2017.09.00710.1016/j.colsurfa.2017.09.007 ↗
3. Sequential optimization of methotrexate encapsulation in micellar nano‐networks of polyethyleneimine ionomer containing redox‐sensitive cross‐links
4. 10.4155/tde.13.4410.4155/tde.13.44 ↗
5. 10.1002/cncr.2273910.1002/cncr.22739 ↗
6. 10.1182/blood.V100.4.1224.h81602001224_1224_123210.1182/blood.V100.4.1224.h81602001224_1224_1232 ↗
7. 10.1021/mp500384d10.1021/mp500384d ↗
8. 10.1054/bjoc.2001.216510.1054/bjoc.2001.2165 ↗
9. 10.1007/s11095-004-7675-510.1007/s11095-004-7675-5 ↗
10. 10.1166/jnn.2016.1073910.1166/jnn.2016.10739 ↗
11. 10.1038/onc.2008.31010.1038/onc.2008.310 ↗
12. 10.1023/A:101500050362910.1023/A:1015000503629 ↗
13. 10.1016/S0142-9612(02)00445-310.1016/S0142-9612(02)00445-3 ↗
14. 10.1517/17425247.2015.96092010.1517/17425247.2015.960920 ↗
15. 10.2217/nnm.12.1110.2217/nnm.12.11 ↗
16. 10.1038/nbt0204-16910.1038/nbt0204-169 ↗
17. Multidrug (pleiotropic) resistance in doxorubicin‐selected variants of the human sarcoma cell line MES‐SA
18. 10.1016/j.bbrc.2006.11.13510.1016/j.bbrc.2006.11.135 ↗
19. 10.1016/j.jconrel.2006.01.00510.1016/j.jconrel.2006.01.005 ↗
20. 10.1016/j.jconrel.2015.05.26810.1016/j.jconrel.2015.05.268 ↗
21. 10.3390/molecules2211192910.3390/molecules22111929 ↗
22. 10.1016/j.msec.2016.10.00810.1016/j.msec.2016.10.008 ↗
23. 10.1111/jvim.1259610.1111/jvim.12596 ↗
24. 10.1016/S0939-6411(00)00075-810.1016/S0939-6411(00)00075-8 ↗
25. 10.1016/j.addr.2013.09.01810.1016/j.addr.2013.09.018 ↗
26. 10.1016/j.jconrel.2007.08.00610.1016/j.jconrel.2007.08.006 ↗
27. 10.1021/bi036214l10.1021/bi036214l ↗
28. 10.1016/j.jconrel.2011.02.03110.1016/j.jconrel.2011.02.031 ↗
29. 10.1038/bjc.1993.33810.1038/bjc.1993.338 ↗
30. 10.1039/c4nr00018h10.1039/c4nr00018h ↗
31. 10.1039/C4PY00687A10.1039/C4PY00687A ↗
32. 10.1002/cyto.99017010710.1002/cyto.990170107 ↗
33. 10.1016/j.addr.2009.12.00210.1016/j.addr.2009.12.002 ↗
34. 10.1016/S0168-3659(98)00009-110.1016/S0168-3659(98)00009-1 ↗
35. 10.15171/bi.2018.2710.15171/bi.2018.27 ↗
36. 10.1093/oxfordjournals.jbchem.a13405310.1093/oxfordjournals.jbchem.a134053 ↗
37. 10.1016/j.colsurfb.2018.10.07210.1016/j.colsurfb.2018.10.072 ↗
38. 10.2174/13894500677770959310.2174/138945006777709593 ↗
39. 10.1002/bip.36001030710.1002/bip.360010307 ↗
40. 10.1021/ma60024a01110.1021/ma60024a011 ↗
41. 10.1016/j.actbio.2013.12.02510.1016/j.actbio.2013.12.025 ↗
42. 10.1039/C7MD00178A10.1039/C7MD00178A ↗
43. 10.1016/j.mito.2014.06.00610.1016/j.mito.2014.06.006 ↗
44. 10.1016/j.compositesb.2006.07.00710.1016/j.compositesb.2006.07.007 ↗
45. 10.1186/1743-8977-7-2210.1186/1743-8977-7-22 ↗
46. 10.1016/0169-409X(95)00039-A10.1016/0169-409X(95)00039-A ↗
47. 10.1196/annals.1359.01210.1196/annals.1359.012 ↗
48. 10.1038/nrd198410.1038/nrd1984 ↗
49. 10.1016/j.canlet.2013.04.02010.1016/j.canlet.2013.04.020 ↗
50. 10.1016/j.jconrel.2015.12.02310.1016/j.jconrel.2015.12.023 ↗
51. 10.1023/A:100969522103810.1023/A:1009695221038 ↗
52. 10.1038/mt.2009.28110.1038/mt.2009.281 ↗
53. 10.1016/j.bbapap.2004.12.01710.1016/j.bbapap.2004.12.017 ↗
54. 10.1021/bm501075610.1021/bm5010756 ↗